false
0002046386
0002046386
2026-10-13
2026-10-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): October 13, 2026
Medline Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
001-43022 |
33-1845288 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
3 Lakes Drive
Northfield,
IL 60093
(Address of principal executive offices, including
zip code)
(847) 949-5500
(Registrant's telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| Class A common stock, par value $0.0001 per share |
MDLN |
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 13, 2026, Joseph P. Baratta notified the Board of Directors (the “Board”) of Medline Inc. (the “Company”)
of his decision to resign from the Board, effective as of December 31, 2026. Mr. Baratta’s decision coincides with his previously
announced departure from Blackstone Inc. and is not the result of any disagreement with the Company related to the Company’s
operations, policies, or practices. The Board is grateful for Mr. Baratta’s service and contributions to the Company.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
Date: October 15, 2026
| |
MEDLINE INC. |
| |
|
|
| |
By: |
/s/
Alex M. Liberman |
| |
|
Name: |
Alex
M. Liberman |
| |
|
Title: |
Chief
Legal Officer |
